About this trial
This Study is comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL).
Patient Profile
High-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL).
Where’s this trial being run?
Beaumont Hospital and St James’s Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | MOR208C310 |
|---|---|
| Number: | 20-35 |
| Full Title: | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL). |
| Principal Investigator: | Prof Elizabeth Vandenberghe |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | MorphoSys AG |
| Recruitment Started: |
Global: 11-May-2021 Ireland: 30-Jun-2021 |
| Global Recruitment Target: | Approx. 880 patients |
|---|---|
| Ireland Recruitment Target: | Approx. 12 patients |